Akari Therapeutics Raises $5.5M via ADS Placement to Advance AKTX-101 Trial
AKTX•Akari Therapeutics has priced a $5.5 million private placement by issuing 1,470,588 ADSs at $3.74 each along with Series H, I and J warrants exercisable at $3.74. Net proceeds will fund advancement of its lead ADC AKTX-101 toward a first-in-human Phase 1 trial by mid-2027.
1. Financing Details
Akari Therapeutics has entered into definitive purchase agreements to issue 1,470,588 unregistered ADSs at $3.74 each, along with Series H, I and J warrants exercisable at $3.74 per ADS. The warrants have terms of 18 months for Series H and 60 months for Series I and J, subject to shareholder approval.
2. Lead ADC Program Advancement
Proceeds will support advancement of AKTX-101, the company’s novel RNA splicing modulator ADC targeting Trop2, toward its first-in-human Phase 1 clinical trial, currently planned for mid-2027.
3. Use of Proceeds and Timeline
The gross $5.5 million financing will close in three tranches between May 27 and July 15, 2026. Net funds are earmarked for working capital, general corporate purposes and potential strategic partnerships.
